ArticleProceedings of the National Academy of Sciences of the United States of America2012
Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Review
- The Contradictory Role of Interleukin-33 in Immune Cells and Tumor Immunity.Cancer management and research · 2020Review
- Interleukin (IL)-33: an orchestrator of immunity from host defence to tissue homeostasis.Clinical & translational immunology · 2020Review
- Costimulation Induces CD4 T Cell Antitumor Immunity via an Innate-like Mechanism.Cell reports · 2019Article
- B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33.Blood advances · 2018Article
- IL-33 in Tumor Immunity: Nothing to Sneeze At.Critical reviews in immunology · 2018Review
- Epithelial-derived IL-33 promotes intestinal tumorigenesis in ApcScientific reports · 2017Article
- Responses to LPS boost effector CD8 T-cell accumulation outside of signals 1 and 2.Cellular & molecular immunology · 2017Article
- Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.Immunotherapy · 2017Review
- Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.Journal of molecular medicine (Berlin, Germany) · 2016Review
- ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice.Blood · 2016Article
- Costimulation Endows Immunotherapeutic CD8 T Cells with IL-36 Responsiveness during Aerobic Glycolysis.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- TLR3-Induced Maturation of Murine Dendritic Cells Regulates CTL Responses by Modulating PD-L1 Trafficking.PloS one · 2016Article
- Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses.Cancer cell · 2015Article
- Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signaling.Immunity, inflammation and disease · 2015Article
- IL-33 isoforms: their future as vaccine adjuvants?Expert review of vaccines · 2015Article
- Trace Levels of Staphylococcal Enterotoxin Bioactivity Are Concealed in a Mucosal Niche during Pulmonary Inflammation.PloS one · 2015Article
- Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+ T and NK cells.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes.PLoS pathogens · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
The synthetic double-stranded RNA poly(I:C) is commonly used as an adjuvant to boost CD8 T-cell function; however, polyinosinic:polycytidylic acid [poly(I:C)] can also suppress autoimmune disease. The mechanism by which a single adjuvant achieves two distinct immunoregulatory roles is unknown. Although it is clear that coadministration of poly(I:C) with antigen elicits strong adjuvant effects in mice, we found that poly(I:C) injection before antigen substantially reduced antigen-dependent CD8 T-cell responses. Notably, CD8 T cells sensitized in poly(I:C)-pretreated mice failed to fully up-regulate IL-33R (ST2), which led to impaired T-cell receptor-independent responses to IL-33. In contrast, nonsensitized effector CD8 T cells responded robustly to IL-33 using a two-signal cytokine mechanism. During an acute lung response to Staphylococcus aureus enterotoxin, peripheral injection of poly(I:C) manifested a suppressive process by inhibiting the differentiation of both antigen- and IL-33-responsive CD8 effectors systemically. These findings highlight that early exposure to double-stranded RNA reverses its role as an adjuvant and, importantly, prevents IL-33R up-regulation on CD8 effector T cells to dampen inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.